Anti‐C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

Franchini, 2013, Hemophilia A in the third millennium, Blood Rev, 27, 179, 10.1016/j.blre.2013.06.002 Carcao, 2012, The diagnosis and management of congenital hemophilia, Semin Thromb Hemost, 38, 727, 10.1055/s-0032-1326786 Dimichele, 2002, Inhibitors: resolving diagnostic and therapeutic dilemmas, Haemophilia, 8, 280, 10.1046/j.1365-2516.2002.00626.x Wight, 2003, The epidemiology of inhibitors in haemophilia A: a systematic review, Haemophilia, 9, 418, 10.1046/j.1365-2516.2003.00780.x Gouw, 2009, The multifactorial etiology of inhibitor development in hemophilia: genetics and environment, Semin Thromb Hemost, 35, 723, 10.1055/s-0029-1245105 Verbruggen, 1995, The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability, Thromb Haemost, 73, 247, 10.1055/s-0038-1653759 Barrow, 2006, Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII, J Thromb Haemost, 4, 2223, 10.1111/j.1538-7836.2006.02135.x Kasper, 1975, Proceedings: a more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh, 34, 869 Miller, 2017, Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors, J Thromb Haemost, 15, 1971, 10.1111/jth.13795 Verbruggen, 2009, Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen, Semin Thromb Hemost, 35, 752, 10.1055/s-0029-1245107 Yada, 2013, Different factor VIII neutralizing effects on anti‐factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor, Br J Haematol, 163, 104, 10.1111/bjh.12473 Hofbauer, 2015, Affinity of FVIII‐specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans, Blood, 125, 1180, 10.1182/blood-2014-09-598268 Cannavo, 2017, Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A, Blood, 129, 1245, 10.1182/blood-2016-06-720086 Eubanks, 2016, A subset of high titer anti‐factor VIII A2 domain antibodies are responsive to treatment with factor VIII, Blood, 127, 2028, 10.1182/blood-2015-09-670034 Meeks, 2009, Non‐classical anti‐factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model, J Thromb Haemost, 7, 658, 10.1111/j.1538-7836.2009.03299.x Collins, 2013, Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization, Br J Haematol, 160, 153, 10.1111/bjh.12091 Kempton, 2014, Toward optimal therapy for inhibitors in hemophilia, Blood, 124, 3365, 10.1182/blood-2014-05-577643 Batsuli, 2016, High‐affinity, non‐inhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors, Blood, 128, 2055, 10.1182/blood-2016-02-701805 Kohler, 1976, Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion, Eur J Immunol, 6, 511, 10.1002/eji.1830060713 Healey, 2007, The humoral response to human factor VIII in hemophilia A mice, J Thromb Haemost, 5, 512, 10.1111/j.1538-7836.2007.02373.x Barrow, 2001, Antigenicity of putative phospholipid membrane‐binding residues in factor VIII, Blood, 97, 169, 10.1182/blood.V97.1.169 Horton, 1993, Gene splicing by overlap extension, Methods Enzymol, 217, 270, 10.1016/0076-6879(93)17067-F Lind, 1995, Novel forms of B‐domain‐deleted recombinant factor VIII molecules. Construction and biochemical characterization, Eur J Biochem, 232, 19, 10.1111/j.1432-1033.1995.tb20776.x Denis, 1998, A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis, Proc Natl Acad Sci USA, 95, 9524, 10.1073/pnas.95.16.9524 Meeks, 2012, A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function, Blood, 120, 2512, 10.1182/blood-2012-02-412361 Lee, 2014 Valentino, 2015, US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors, Haemophilia, 21, 559, 10.1111/hae.12730 Vlot, 1995, The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor, Blood, 85, 3150, 10.1182/blood.V85.11.3150.bloodjournal85113150 Meeks, 2007, Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation, Blood, 110, 4234, 10.1182/blood-2007-06-096842 Astermark, 2006, Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors, Haemophilia, 12, 8, 10.1111/j.1365-2516.2006.01360.x Prescott, 1997, The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups, Blood, 89, 3663, 10.1182/blood.V89.10.3663 Scandella, 2001, In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic, Thromb Res, 101, 377, 10.1016/S0049-3848(00)00418-7 Lavigne‐Lissalde, 2007, Molecular characterization of human B domain‐specific anti‐factor VIII monoclonal antibodies generated in transgenic mice, Thromb Haemost, 98, 138, 10.1160/TH06-09-0510 Dazzi, 1996, High incidence of anti‐FVIII antibodies against non‐coagulant epitopes in haemophilia A patients: a possible role for the half‐life of transfused FVIII, Br J Haematol, 93, 688, 10.1046/j.1365-2141.1996.d01-1705.x Miller, 2013, Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study, J Thromb Haemost, 11, 1300, 10.1111/jth.12259 Hartholt, 2017, To serve and protect: the modulatory role of von Willebrand factor on factor VIII immunogenicity, Blood Rev, 31, 339, 10.1016/j.blre.2017.07.001 Lenting, 1999, The light chain of factor VIII comprises a binding site for low density lipoprotein receptor‐related protein, J Biol Chem, 274, 23734, 10.1074/jbc.274.34.23734